Patents by Inventor Reinaldo Jones

Reinaldo Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
    Publication number: 20220389004
    Abstract: The present invention relates to fused imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Application
    Filed: August 26, 2019
    Publication date: December 8, 2022
    Inventors: Richard D. CALDWELL, Lesley LIU-BUJALSKI, Justin POTNICK, Constantin NEAGU, Shashank KULKARNI, Reinaldo JONES, Hui QIU
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 11098041
    Abstract: Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: August 24, 2021
    Assignee: Merck Patent GmbH
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 10413562
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: September 17, 2019
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF
    Publication number: 20190233417
    Abstract: Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors.
    Type: Application
    Filed: April 8, 2019
    Publication date: August 1, 2019
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 10329270
    Abstract: The present invention relates to pyridine, pyrimidine, pyrazine, and pyridazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: June 25, 2019
    Assignee: Merck Patent GmbH
    Inventors: Hui Qiu, Richard D. Caldwell, Constantin Neagu, Igor Mochalkin, Lesley Liu-Bujalski, Reinaldo Jones, Devon Tate, Theresa L. Johnson, Anna Gardberg
  • Substituted pyrazoles as IRAK inhibitors
    Patent number: 10314841
    Abstract: The present invention provides compounds of Formula (II) for the treatment of cancer, rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: June 11, 2019
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Reinaldo Jones
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 10253023
    Abstract: The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: April 9, 2019
    Assignee: Merck Patent GmbH
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • Cyclic amine azaheterocyclic carboxamides
    Patent number: 10087166
    Abstract: The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 2, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Xiaoling Chen, Constantin Neagu, Reinaldo Jones, Yufang Xiao, Igor Mochalkin
  • COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY
    Publication number: 20180243324
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Application
    Filed: May 3, 2018
    Publication date: August 30, 2018
    Inventors: Brian L. HODOUS, Lesley LIU-BUJALSKI, Reinaldo JONES, Donald BANKSTON, Theresa L. JOHNSON, Igor MOCHALKIN, Ngan NGUYEN, Hui QIU, Andreas GOUTOPOULOS, Nadia BRUGGER
  • Heteroaryl compounds as IRAK inhibitors and uses thereof
    Patent number: 10030013
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 24, 2018
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Reinaldo Jones, Annie Cho Won, Ngan Nguyen, Theresa L. Johnson, Lizbeth Celeste Deselm, Kausik Panda
  • Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 10016448
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: July 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof
    Patent number: 10005784
    Abstract: The present invention relates to pyridine, pyrimidine, and pyrazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: June 26, 2018
    Assignee: Merck Patent GmbH
    Inventors: Lesley Liu-Bujalski, Ngan Nguyen, Hui Qiu, Reinaldo Jones, Igor Mochalkin, Richard D. Caldwell
  • PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS
    Publication number: 20180169094
    Abstract: The present invention provides compounds of Formula (II) for the treatment of cancer, rheumatoid arthritis and other diseases.
    Type: Application
    Filed: January 9, 2015
    Publication date: June 21, 2018
    Inventors: Catherine JORAND-LEBRUN, Reinaldo JONES
  • HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF
    Publication number: 20180002327
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Application
    Filed: September 12, 2017
    Publication date: January 4, 2018
    Inventors: Catherine JORAND-LEBRUN, Reinaldo JONES, Annie Cho WON, Ngan NGUYEN, Theresa L. JOHNSON, Lizbeth Celeste DESELM, Kausik PANDA
  • Heteroaryl compounds as IRAK inhibitors and uses thereof
    Patent number: 9790221
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: October 17, 2017
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Reinaldo Jones, Annie Cho Won, Ngan Nguyen, Theresa L. Johnson, Lizbeth Celeste Deselm, Kausik Panda
  • Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof
    Patent number: 9738648
    Abstract: The present invention relates to pyridine, pyrimidine, and pyrazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: August 22, 2017
    Assignee: Merck Patent GmbH
    Inventors: Lesley Liu-Bujalski, Ngan Nguyen, Hui Qiu, Reinaldo Jones, Igor Mochalkin, Richard D. Caldwell
  • PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF
    Publication number: 20170226113
    Abstract: The present invention relates to pyridine, pyrimidine, and pyrazene compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 10, 2017
    Inventors: Lesley LIU-BUJALSKI, Ngan NGUYEN, Hui QIU, Reinaldo JONES, Igor MOCHALKIN, Richard D. CALDWELL
  • COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY
    Publication number: 20170136048
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 18, 2017
    Inventors: Brian L. HODOUS, Lesley LIU-BUJALSKI, Reinaldo JONES, Donald BANKSTON, Theresa L. JOHNSON, Igor MOCHALKIN, Ngan NGUYEN, Hui QIU, Andreas GOUTOPOULOS, Nadia BRUGGER
  • Cyclic Amine Azaheterocyclic Carboxamides
    Publication number: 20170129877
    Abstract: The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: January 24, 2017
    Publication date: May 11, 2017
    Inventors: Bayard R. HUCK, Xiaoling CHEN, Constantin NEAGU, Reinaldo JONES, Yufang XIAO, Igor MOCHALKIN
  • Cyclic amine azaheterocyclic carboxamides
    Patent number: 9586938
    Abstract: The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: March 7, 2017
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Xiaoling Chen, Constantin Neagu, Reinaldo Jones, Yufang Xiao, Igor Mochalkin